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Abstract
The non-integrin laminin receptor, here designated the 37-kDa/67-kDa laminin receptor (LRP/LR), is involved in many
physiologically relevant processes, as well as numerous pathological conditions. The overexpression of LRP/LR on various
cancerous cell lines plays critical roles in tumour metastasis and angiogenesis. This study investigated whether LRP/LR is
implicated in the maintenance of cellular viability in lung and cervical cancer cell lines. Here we show a significant reduction
in cellular viability in the aforementioned cell lines as a result of the siRNA-mediated downregulation of LRP. This reduction
in cellular viability is due to increased apoptotic processes, reflected by the loss of nuclear integrity and the significant
increase in the activity of caspase-3. These results indicate that LRP/LR is involved in the maintenance of cellular viability in
tumorigenic lung and cervix uteri cells through the blockage of apoptosis. Knockdown of LRP/LR by siRNA might represent
an alternative therapeutic strategy for the treatment of lung and cervical cancer.
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Introduction
Laminins belong to a large family of extracellular matrix
proteins that are involved in a number of biologically significant
processes, including cell differentiation, migration, adhesion,
growth and signalling [1]. The effects of laminins are often
mediated through their interaction with integrin and non-integrin
laminin-binding proteins, which function as receptors and link
laminin in the extracellular matrix to intracellular signalling
cascades [1].
A major laminin binding partner is a multifunctional protein,
designated here as the 37-kDa/67-kDa laminin receptor (LRP/
LR). The 67-kDa laminin receptor is formed from the 37-kDa
laminin receptor precursor [2,3]. The exact mechanism of this
conversion is currently still elusive, however, some studies have
suggested that the unglycosylated 37-kDa form becomes acylated
at Ser2 through the action of fatty acids; and this acylation is
a critical step in the conversion of the 37-kDa form to the 67-kDa
form [4,5].
LRP/LR is a non-integrin cell surface receptor exhibiting a high
affinity to laminin-1 [6], and has been found to localize in the
cytoplasm [7,8,9], on the cell surface [10,11], in the perinuclear
compartment [7,12,13] and in the nucleus [12,13]. In each of
these locations, LRP/LR is involved in numerous physiological
processes including protein synthesis [8], the maturation of the
40S ribosomal subunit [8], acting as a receptor for extracellular
matrix components e.g. carbohydrates and elastin [14], interac-
tions with cellular prion protein [13,15] and associations with the
histones [12].
In addition to its numerous physiological roles, LRP has been
implicated in a number of pathological processes - it serves as
a receptor for infectious prions [16], certain bacteria [17], and
various viruses [18,19,20]. Most notably, a number of cancer
types, such as gastric [21], colon [22], colorectal [23], cervical
[24], breast [25], lung [26], ovarian [27], pancreatic [28] and
prostate [29] cancers, reveal an overexpression of the 67-kDa LR
on their cell surface, the use of anti-LRP/LR specific antibodies
significantly reduced the adhesion and invasion of cancer cells
in vitro [6,30], key components of metastasis. A strong correlation
has also been established between LRP/LR and cancer angio-
genesis, with expression of this protein correlating to increased
tumour angiogenesis [31]; we recently discovered that that the
LRP/LR specific antibody, W3, blocked angiogenesis [32].
Since the targeting of LRP/LR on cancerous cells has been
proven to be successful with respect to the reduction of tumour
metastasis [6,30], the role of this receptor on cancer cell viability
and survival has become a topic of great interest. This study,
therefore, aimed to assess the effect of the siRNA-mediated
knockdown of LRP on the viability and survival of lung and
cervical cancer cells and to determine the possible the mechanistic
approaches of the observed effects. Lung and cervical cancer cells
were chosen for this study as they represent the top two diagnosed
cancer types in Southern African men and women respectively.
We have shown in this study that the siRNA-mediated knockdown
of LRP/LR in A549 and HeLa cells caused a significant reduction
in the viability of these cells. Additionally, it was shown that this
reduction in cellular viability was as a consequence of the cells
undergoing apoptosis.
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Materials and Methods
Cell Culture and Conditions
A549 and HeLa cells were obtained from ATCC, cultured in
Dulbecco’s Modified Eagle Medium (DMEM) supplemented with
10% Fetal Calf Serum (FCS) and 1% penicillin/streptomycin and
maintained in a humidified incubator at 37uC with 95% air and
5% CO2.
Flow Cytometry
Flow cytometry was performed to determine the cell surface
levels of LRP on A549 and HeLa cells. Briefly, cells were
detached, pelleted and fixed in 4% paraformaldehyde. Cells were
then incubated in 30 mg/ml of the primary LRP-specific antibody
IgG1-iS18 in EpicsTM Sheath Fluid for 1 h. Cells were then
washed in EpicsTM Sheath Fluid and incubated in 30 mg/ml goat
anti-rabbit IgG human ads-FITC secondary antibody (Beckman
Coulter) in EpicsTM Sheath Fluid. Subsequently the cells were
washed in EpicsTM Sheath Fluid and analysed.
Western Blotting
Western blotting was used to determine the total and down-
regulated protein levels of LRP (b-actin used as a loading control)
post-transfection with siRNA-LAMR1. Briefly, cells were lysed,
protein levels quantified and 5 mg of crude cell lysate resolved on
a 12% polyacrylamide gel. The proteins were subsequently
transferred to a nitrocellulose membrane by semi-dry electro-
blotting for 45 min. The membrane was blocked in 3% BSA,
incubated in a 1:10 000 solution of the LRP-specific primary
antibody IgG1-iS18 in 3% BSA in PBS-Tween for 1 h at 4uC with
shaking. The membrane was subsequently washed in PBS-Tween,
further incubated in a 1:10 000 solution of anti-human POD
secondary antibody in 3% BSA in PBS-Tween for 1 h at 25uC
with shaking, washed as before and analysed.
siRNA-mediated Downregulation of LRP
A549 and HeLa cells were transfected for LRP knockdown with
siRNA purchased from Dharmacon, Cat # J-013303-08, accord-
ing to manufacturers instruction using DharmaFECTH 1 trans-
fection reagent. Control siRNA used – Cat # D-001810-01-05.
MTT Assay
0.66104 A549 and 36103 HeLa cells were seeded in the wells of
a 96 well plate. Cells were then transfected with siRNA-scr or
siRNA-LAMR1, as described, and allowed to incubate in
a humidified incubator at 37uC with 95% air and 5% CO2 for
72 h. 10 mg of MTT dissolved in PBS was then added to each well
an allowed to incubate for 2 h as before. The media was discarded
from each well and the purple formazan crystals dissolved in
200 mL DMSO. The absorbance of each well was measured at
570 nm using an ELISA plate reader.
Immunofluorescence Microscopy
46105 A549 and 3.56105 HeLa cells were seeded onto
coverslips in the wells of a 6 well plate. Cells were transfected
with siRNA-scr and siRNA-LAMR1, as described, and incubated
in a humidified incubator at 37uC with 95% air and 5% CO2 for
72 h. The coverslips were removed and cells fixed in 1%
paraformaldehyde, stained with Hoechst 33342 (1:10 000 in
PBS) and analysed using fluorescence microscopy.
Caspase-3 Activation Assay
46105 A549 and 3.56105 HeLa cells were seeded into the wells
of a 6 well plate. Cells were transfected with siRNA-scr and
siRNA-LAMR1, as described, and incubated in a humidified
incubator at 37uC with 95% air and 5% CO2 for 72 h. The
activity of caspase-3 was analysed using the Caspase-3 Assay Kit
(Sigma-Aldrich) according to the manufacturers instruction.
Statistical Evaluation
Data was statistically analyzed with a Dunnett’s test using
GraphPad InStat. Results were considered statistically significant
when the p-value was less than 0.05.
Results
Lung and Cervical Cancer Cells Display High Cell Surface
Levels of LRP/LR and Total Levels of LRP
Since the overexpression of LRP has been observed in
numerous cancerous cell lines, the cell surface levels of LRP/LR
and total levels of LRP on A549 and HeLa cells was determined
by flow cytometric analysis and western blotting respectively
(Figure 1). Flow cytometry revealed that 83% and 80% of A549
and HeLa cells, respectively, expressed LRP/LR on their cell
surface (Figure 1A and 1B), these values are high in comparison to
the LRP/LR cell surface level (57%) of the non-tumorigenic cell
line, NIH 3T3, (data not shown) and confirms the results obtained
in previous studies [30]. LRP was found to be expressed in both
cell lines by western blotting, additionally, subsequent densitomet-
ric analysis of the obtained western blot signals revealed that A549
and HeLa cells display similar levels of this protein (Figure 1C).
Determination of the siRNA-mediated Downregulation of
LRP Expression in Lung and Cervical Cancer Cells
The level of LRP expression in A549 and HeLa cells post-
transfection with siRNA-LAMR1 was determined using western
blotting and quantified by densitometry (Figure 2). Densitometric
analysis of the obtained western blot signals revealed that A549
(Figure 2A) and HeLa (Figure 2B) cells transfected with siRNA-
LAMR1 expressed 80% and 60% less LRP, respectively,
compared to non-transfected controls which were set to 100%.
The siRNA-mediated Knockdown of LRP Expression
Causes a Significant Reduction in the Viability of Lung
and Cervical Cancer Cells
The effect of the siRNA-mediated downregulation of LRP
protein expression on cellular viability in A549 and HeLa cells was
determined using an MTT assay. Cells were incubated with 8 mM
PCA (a compound known to decrease cellular viability through the
induction of apoptosis [33]) as a positive control and transfected
with a non-targeting siRNA (siRNA-scr) as a negative control.
8 mM PCA and siRNA-LAMR1 values were compared to siRNA-
scr values, which had been set to 100%. The results from this assay
indicate that the significant (* p,0.05, ** p,0.01) decrease in the
viability of A549 and HeLa cells (13% and 18%, respectively) is as
a result of the reduced expression of this protein (Figure 3).
The siRNA-mediated Downregulation of LRP Expression
Causes a Loss in Nuclear Morphology in Lung and
Cervical Cancer Cells
To investigate a possible mechanism for the observed decease in
cellular viability in response to LRP knockdown in A549 and
HeLa cells, the nuclear morphology of the aforementioned cells
was assessed. A549 and HeLa cells were transfected with siRNA-
LRP/LR Mediates Cell Viability
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LAMR1, incubated with 8 mM PCA (a known apoptosis inducer
[33]) as a positive control and transfected with siRNA-scr (negative
control). The cells were then stained with the fluorescent nuclear
dye Hoechst 33324 and viewed on an immunofluorescence
microscope. The nuclear images obtained for siRNA-LAMR1
were compared to siRNA-scr – the nuclei appear constricted and
definite loss of nuclear morphology and integrity is observed
(Figure 4–white arrows). Additionally, the percentage of cells
displaying morphological changes was determined by counting the
number of cells with and without nuclear morphological changes
in 3 micrographs. 56% of A549 cells and 91% of HeLa cells
exhibited nuclear morphological changes in response to siRNA-
LAMR1 treatment (7% and 8% of siRNA-scr treated A549 cells
and HeLa cells, respectively, showed nuclear morphological
changes).
siRNA-mediated Knockdown of LRP Caused a Significant
Increase in Caspase-3 Activity in Lung and Cervical
Cancer Cells
The activity of the apoptosis-associated effector protein,
caspase-3, in response to the siRNA-mediated downregulation of
LRP expression in A549 and HeLa cells was assessed using
a Caspase-3 activation assay. A549 and HeLa cells were
transfected with siRNA-LAMR1, incubated with 8 mM PCA
(an apoptosis inducer [33] - positive control) and transfected with
siRNA-scr (negative control). The activity of caspase-3 from cells
transfected with siRNA-LAMR1 was compared to those trans-
fected with siRNA-scr (which had been set to 100%); these results
reveal a significant (** p,0.01, *** p,0.001) increase in caspase-3
activity in A549 and HeLa cells transfected with siRNA-LAMR1
(9% and 83%, respectively) (Figure 5).
Discussion
The role of the laminin receptor in cancer progression has been
a topic of great interest for many years and has therefore been
extensively investigated. Numerous studies have implicated cell
surface LRP/LR in the progression of cancer – this receptor is
overexpressed on the surface of a number of cancerous cell lines,
affording them the ability to metastasize and invade surrounding
tissues [6,30]. Given that LRP/LR is involved in a number of
cellular processes and is found in numerous cellular locations (the
cell surface, the cytoplasm, the perinuclear compartment and the
nucleus), additional roles of this receptor in cancer progression
have been suggested.
To confirm the expression of LRP/LR in A549 and HeLa cells,
the cell surface and total levels of this protein was investigated
using flow cytometry and western blotting, respectively (Figure 1).
Figure 1. Determination of cell surface LRP/LR and total LRP levels on A549 and HeLa cells. A) 83% of A549 and B) 80% of HeLa cells
displayed LRP/LR on their surface (left and right peaks are representative of non-labelled cells and cells incubated initially with the anti-LRP IgG1-iS18
antibody and subsequently with the goat anti-rabbit IgG human ads-FITC secondary antibody, respectively). C) A549 (lanes 1–3) and HeLa (lanes 4–6)
cells express LRP and densitometric analysis revealed non-significant (p.0.05) differences in total LRP levels between the two cell lines.
doi:10.1371/journal.pone.0057409.g001
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The tumorigenic lung and cervical cancer cells both displayed
LRP/LR on their surface, and the level of this protein on the
surface of these cells was found to be higher than the level
observed in the non-tumorigenic cell line NIH 3T3 (mouse
embryonic fibroblast). This finding confirms previous research,
and suggests a role for this receptor in the progression of cells from
being normal to becoming cancerous. Additionally, the tumori-
genic lung and cervical cancer cells both express LRP internally,
and the difference in the internal level of this protein in these cell
lines is insignificant.
Figure 2. siRNA-mediated downregulation of LRP expression in A549 and HeLa cells. The expression level of LRP in A549 and HeLa cells
was investigated 72 h post-transfection with siRNA-LAMR1. Densitometric analysis of western blot signals revealed a significant (** p,0.01) 83% and
60% reduction in LRP protein expression in A) A549 and B) HeLa cells, respectively, compared to control non-transfected cells (set to 100%).
doi:10.1371/journal.pone.0057409.g002
Figure 3. The effect of siRNA-mediated downregulation of LRP on cell survival in A549 and HeLa cells. The viability of A549 and HeLa
cells was analyzed 72 h post-transfection using an MTT assay. A) A549 and B) HeLa cells transfected with siRNA-LAMR1 revealed a significant (*
p,0.05, ** p,0.01) 13% and 18% decrease in cellular viability, respectively, compared to siRNA-scr which had been set to 100% (8 mM PCA was used
as positive control).
doi:10.1371/journal.pone.0057409.g003
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To investigate the role of LRP/LR in cancer related/cytotoxic
processes, its expression was significantly decreased in the
tumorigenic lung and cervical cancer cells. siRNA directed against
LRP mRNA was transfected into the aforementioned cells and the
percentage of LRP downregulation assessed by densitometric
analysis of obtained western blot signals (Figure 2). The level of
LRP expression was reduced by 83% and 60% in A549 and HeLa
cells, respectively, which indicates the efficacy of the siRNA used.
The effect of the knockdown of LRP expression on the viability
of cancerous cells, which is an important characteristic of the
disease, was investigated. LRP downregulation was found to
correlate with a significant reduction in the viability of A549 and
HeLa cells (Figure 3), indicating a crucial role for LRP in this
process. Since the maintenance of cellular viability is imperative
for the propagation of cancerous cells, the suggestion that LRP is
involved in the maintenance of this process further implicates this
protein in the disease.
A reduction in cellular viability was however also noticed
between non-transfected and siRNA-scr samples in HeLa cells
(data not shown) and the DharmaFECTH 1 transfection reagent
was shown to be the causative agent in this decrease (see
supplementary data - Figure S1).
In order to investigate if apoptosis (a form of programmed cell
death) was induced in tumorigenic lung and cervical cancer cells as
Figure 4. The effect of the siRNA-mediated downregulation of LRP on nuclear morphology. 72 h post-transfection, A549 and HeLa cells
were stained with Hoechst 33342 and viewed by immunofluorescence microscopy. Cells transfected with siRNA-LAMR1 exhibit decreased nuclear
integrity - indicated by white arrows (8 mM PCA was used as positive control).
doi:10.1371/journal.pone.0057409.g004
Figure 5. The effect of the siRNA-mediated downregulation of LRP on caspase-3 activity. The activity of the apoptosis-associated protein,
caspase-3, in A549 and HeLa cells was analysed 72 h post-transfection. A) A549 and B) HeLa cells transfected with siRNA-LAMR1 reveal a significant (*
p,0.05, ** p,0.001) 9% and 83% increase in caspase-3 activity, respectively, compared to the siRNA-scr which has been set to 100% (8 mM PCA was
used as positive control).
doi:10.1371/journal.pone.0057409.g005
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a consequence of LRP knockdown, and hence being responsible
for the observed reduction in cellular viability, we assessed possible
changes in the nuclear morphology of the cell and the level of
activity of the apoptosis-associated effector protein – caspase-3 (key
processes indicative of apoptosis induction [34,35,36,37,38]). The
presence of apoptotic A549 and HeLa cells post-transfection with
siRNA-LAMR1 were identified by visible disruptions in their
nuclear morphology (Figure 4) as well as by the significant increase
in the activity caspase-3 (Figure 5).
The role of LRP in the maintenance of cellular viability has
been reported in previous studies [7], additionally, the induction of
apoptosis in cancerous cells in response to LRP downregulation
has also been demonstrated [39]. This study has confirmed the
role of LRP in the maintenance of cellular viability as well as the
induction of apoptosis subsequent to the knockdown of this
protein. Further, this study has revealed that the induction of
apoptosis is mediated by both a loss in nuclear integrity and
significantly increased activity of caspase-3 in these cells.
Since the laminin receptor is physiologically functional in the
perinuclear compartment [7,12,13] and the nucleus [12,13], it was
not surprising that the knockdown of this receptor would affect the
integrity of the nucleus. Both the disruption of nuclear morphology
and the increased activity of apoptosis-associated protein, caspase-
3, are indicative of apoptosis, suggesting a pivotal role for LRP/
LR in the blockage of this form of cell death. However,
quantification revealed that 91% of siRNA-LAMR1 treated HeLa
cells but only 56% of siRNA-LAMR1 treated A549 cells revealed
nuclear morphological changes (7% and 8% of siRNA-scr treated
A549 and Hela cells, respectively, revealed nuclear morphological
changes). Since the knockdown of LRP in HeLa cells (60%) was
lower compared to A549 cells (83%) we suggest that LRP/LR
impedes apoptosis to a greater extent in cervical cancer cells
compared to lung cancer cells. Since 83% of HeLa cells but only
9% of A549 cells revealed increased caspase-3 activity following
siRNA-LAMR1 treatment, we further suggest that apoptosis in
lung cancer cells may occur predominantly via caspase-3 in-
dependent mechanisms such as EndoG and/or AIF mediated
processes.
The functions of LRP/LR in cancer propagation are numerous:
increased invasion [6,30], metastasis [6,30] and cellular pro-
liferation [7] as well as decreased cellular viability [7] and
apoptosis [39] are mediated by this protein. Targeting LRP/LR
can therefore be developed as a strategy to hamper the above-
mentioned processes implicated in cancer progression. Addition-
ally, targeting LRP/LR for the possible treatment of these
processes have been achieved in a number of cancerous cell lines.
This therefore suggests that an LRP/LR related therapy could
potentially be utilized for the treatment of numerous distinct
cancers. It must however be stressed that this receptor is involved
in many physiological processes in normal cells, including cell
growth, differentiation, movement and attachment [9,11], and the
knockdown of LRP in these cells would result in undesirable
homeostatic disruptions. The targeting of LRP solely on cancerous
cells is therefore imperative for its use as a therapeutic alternative.
Supporting Information
Figure S1 The effect of siRNA-scr and DharmaFECTH 1
reagent on cellular viability. Cells were incubated with
siRNA-scr, DharmaFECTH 1 reagent or both, and 72 h later,
cellular viability was assessed using an MTT assay. Cells
transfected with siRNA-scr display similar viability, while
DharmaFECTH 1 and siRNA-scr+DharmaFECTH 1 treated cells
display an 8% and 9% decrease in cell viability, respectively,
compared to control cells (incubated for 72 h in DMEM
containing 10% (v/v) FCS).
(TIF)
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